Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NANO Follow-Up Study
NCT05977400Phase 3Not yet recruiting
- Sponsor
- Sharp HealthCare
- Start
- Apr 2024
- Primary completion
- Mar 2029
- Modality
- Nanoparticles, Implantable Devices, Transdermal Patches
- Countries
- 2
01
Overview
A Phase 3 trial of ampicillin, gentamicin in sepsis, sponsored by Sharp HealthCare. Planned start Apr 2024; status: not yet recruiting.
02
Drugs
ampicillingentamicin
03
Conditions
sepsis
Beyond the preview
Go deeper on NCT05977400.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05977400.